Abstract
The presence of p53 mutation or deletion predicts for poor response to conventional therapy in chronic lymphocytic leukemia (CLL). We sought to determine whether the humanized anti-CD52 antibody alemtuzumab was effective in this patient group. Thirty-six patients with fludarabine-refractory CLL were treated with alemtuzumab, 15 (42%) of whom had p53 mutations or deletions. Clinical responses in patients with p53 mutations, deletions, or both were noted in 6 (40%) of 15 versus 4 (19%) of 21 of patients without. The median response duration for this subset of patients was 8 months (range, 3-17 months). These data suggest that alemtuzumab may be an effective therapy for patients with CLL with p53 mutations or deletions.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Aged
-
Alemtuzumab
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm / administration & dosage*
-
Antineoplastic Agents / administration & dosage*
-
Drug Evaluation
-
Drug Resistance
-
Genes, p53*
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
-
Male
-
Middle Aged
-
Mutation
-
Prognosis
-
Retrospective Studies
-
Sequence Deletion
-
Treatment Outcome
-
Vidarabine / analogs & derivatives*
-
Vidarabine / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Antineoplastic Agents
-
Alemtuzumab
-
Vidarabine
-
fludarabine